[Comparison of triperidol with perphenazine in schizophrenic psychoses. Effect on the photomyoclonic threshold].
D000293:Adolescent; D000328:Adult; D000928:Antidepressive Agents / Q000627:therapeutic use*; D002090:Butyrophenones / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003865:Major Depressive Disorder / Q000188:drug therapy; D005260:Female; D005461:Fluorine / Q000627:therapeutic use; D006801:Humans; D008027:Light; D008297:Male; D008875:Middle Aged; D009207:Myoclonus / Q000139:chemically induced; D010546:Perphenazine / Q000627:therapeutic use*; D010880:Piperidines / Q000627:therapeutic use*; D010919:Placebos; D012018:Reflex; D012559:Schizophrenia / Q000188:drug therapy*; D014272:Trifluperidol / Q000009:adverse effects / Q000627:therapeutic use
D000928:Antidepressive Agents; D002090:Butyrophenones; D010880:Piperidines; D010919:Placebos; D005461:Fluorine; D010546:Perphenazine; D014272:Trifluperidol
Srovnání triperidolu s perphenazinem u schizofrenních psychóz vliv na fotomyoklonický práh.